Abstract
Spinal muscular atrophy (SMA) is the most common genetically inherited neurodegenerative disease resulting in infant mortality. SMA is caused by genetic deletion or mutation in the survival of motor neuron 1 (SMN1) gene, which results in reduced levels of the survival of motor neuron (SMN) protein. SMN protein deficiency preferentially affects α- motor neurons, leading to their degeneration and subsequent atrophy of limb and trunk muscles, progressing to death in severe forms of the disease. More recent studies have shown that SMN protein depletion is detrimental to the functioning of other tissues including skeletal muscle, heart, autonomic and enteric nervous systems, metabolic/endocrine (e.g. pancreas), lymphatic, bone and reproductive system. In this review, we summarize studies discussing SMN protein’s function in various cell and tissue types and their involvement in the context of SMA disease etiology. Taken together, these studies indicate that SMA is a multi-organ disease, which suggests that truly effective disease intervention may require body-wide correction of SMN protein levels.
Keywords: Gene therapy, motor neuron, neuromuscular disease, spinal muscular atrophy, survival of motor neuron, therapeutics.
Current Molecular Medicine
Title:Spinal Muscular Atrophy: More than a Disease of Motor Neurons?
Volume: 16 Issue: 9
Author(s): L. A. Nash, J. K. Burns, J. Warman Chardon, R. Kothary and R. J. Parks
Affiliation:
Keywords: Gene therapy, motor neuron, neuromuscular disease, spinal muscular atrophy, survival of motor neuron, therapeutics.
Abstract: Spinal muscular atrophy (SMA) is the most common genetically inherited neurodegenerative disease resulting in infant mortality. SMA is caused by genetic deletion or mutation in the survival of motor neuron 1 (SMN1) gene, which results in reduced levels of the survival of motor neuron (SMN) protein. SMN protein deficiency preferentially affects α- motor neurons, leading to their degeneration and subsequent atrophy of limb and trunk muscles, progressing to death in severe forms of the disease. More recent studies have shown that SMN protein depletion is detrimental to the functioning of other tissues including skeletal muscle, heart, autonomic and enteric nervous systems, metabolic/endocrine (e.g. pancreas), lymphatic, bone and reproductive system. In this review, we summarize studies discussing SMN protein’s function in various cell and tissue types and their involvement in the context of SMA disease etiology. Taken together, these studies indicate that SMA is a multi-organ disease, which suggests that truly effective disease intervention may require body-wide correction of SMN protein levels.
Export Options
About this article
Cite this article as:
Nash A. L., Burns K. J., Chardon Warman J., Kothary R. and Parks J. R., Spinal Muscular Atrophy: More than a Disease of Motor Neurons?, Current Molecular Medicine 2016; 16 (9) . https://dx.doi.org/10.2174/1566524016666161128113338
DOI https://dx.doi.org/10.2174/1566524016666161128113338 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Amino Acids in the Modulation of Cardiac Metabolism During Ischemia and Heart Failure
Current Pharmaceutical Design Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice
CNS & Neurological Disorders - Drug Targets Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine Diseases
Current Pharmaceutical Biotechnology Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson’s Disease Associated Mutations
Current Protein & Peptide Science Origin and Expansion of Trinucleotide Repeats and Neurological Disorders
Current Genomics Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Current Topics in Medicinal Chemistry The Fall in Older Adults: Physical and Cognitive Problems
Current Aging Science Genome-Wide Integrated Analyses of Androgen Receptor Signaling in Prostate Cancer Based on High-Throughput Technology
Current Drug Targets Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Disorders of Protein Biogenesis and Stability
Protein & Peptide Letters Nutrition and Bone Health: Its Relationship to Osteoporosis
Current Nutrition & Food Science Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions
CNS & Neurological Disorders - Drug Targets Pompe Disease: From New Views on Pathophysiology to Innovative Therapeutic Strategies
Current Pharmaceutical Biotechnology Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases
CNS & Neurological Disorders - Drug Targets Michael Acceptors as Cysteine Protease Inhibitors
Mini-Reviews in Medicinal Chemistry Controlling Apoptosis by Inhibition of Caspases
Current Medicinal Chemistry Stem Cells in Skeletal Tissue Engineering: Technologies and Models
Current Stem Cell Research & Therapy Electroporation Gene Therapy: New Developments In Vivo and In Vitro
Current Gene Therapy